<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137822</url>
  </required_header>
  <id_info>
    <org_study_id>2019-IMM101IMM-EU</org_study_id>
    <nct_id>NCT04137822</nct_id>
  </id_info>
  <brief_title>Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impatients N.V. trading as myTomorrows</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immodulon Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Impatients N.V. trading as myTomorrows</source>
  <brief_summary>
    <textblock>
      An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a&#xD;
      heat-killed preparation, treatment is not associated with the potential side-effects of&#xD;
      delivering live or attenuated organisms.&#xD;
&#xD;
      Five studies with IMM-101 have been completed including a 110-patient randomised Phase II&#xD;
      study in pancreatic cancer and exploratory studies in other solid tumours (melanoma,&#xD;
      colorectal cancer and advanced melanoma).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Cancer Stage IV</condition>
  <condition>Pancreatic Cancer Stage III</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMM-101</intervention_name>
    <description>IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.</description>
    <other_name>Heat-killed whole cell M. obuense</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        This Expanded Access Program is available for patients of 18 years or older with advanced&#xD;
        pancreatic cancer for whom, in the opinion of their treating physician, other treatment&#xD;
        options or clinical trials in this indication are unsuitable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Female patient of child-bearing potential who is not, in the opinion of the physician,&#xD;
        using an approved method of birth control (e.g., physical barrier [patient and partner],&#xD;
        contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Costa Neves M, Giakoustidis A, Stamp G, Gaya A, Mudan S. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus. 2015 Dec 26;7(12):e435. doi: 10.7759/cureus.435.</citation>
    <PMID>26870619</PMID>
  </reference>
  <results_reference>
    <citation>Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Mart√≠n AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11.</citation>
    <PMID>27727233</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

